Jailbird Prescriptions Cost Doc His DEA License
Published Date: 10/9/2026
Notice
Summary
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registrations Revoked Effective Nov 9, 2026
The Drug Enforcement Administration revoked Vladimir Romaniv, P.A.'s DEA Certificates of Registration Nos. MR2205602, MR6587919, and MR7746184. The Order also denies any pending application to renew or modify his registration and denies any pending application for additional registration in New York, Massachusetts, or New Jersey. The Order is effective November 9, 2026.
Earlier Immediate Suspension of Two Registrations
On November 10, 2025, the DEA issued an Order to Show Cause and Immediate Suspension of Registration for Vladimir Romaniv, P.A. that immediately suspended DEA Certificates of Registration Nos. MR2205602 and MR6587919 pursuant to 21 U.S.C. 824(d). The DEA alleged that continued registration posed an imminent danger to public health or safety.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
2026-20748, Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
Previous / Next Documents
Previous: 2026-20747, Combined Notice Of Filings
The Federal Energy Regulatory Commission got a bunch of filings from natural gas companies about new rates and agreements starting October and November 2026. These changes could affect customers and partners by updating prices and contract terms, with some filings effective as soon as October 1. If you want to share your thoughts, comments are due by October 13, 2026, so don’t miss out!
Next: 2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.